Takeda Pharmaceutical (TAK) Short Interest Ratio & Short Volume → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Free TAK Stock Alerts $13.24 -0.13 (-0.97%) (As of 03:34 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Takeda Pharmaceutical Short Interest DataCurrent Short Volume6,280,000 sharesPrevious Short Volume5,970,000 sharesChange Vs. Previous Month+5.19%Dollar Volume Sold Short$82.17 millionShort Interest Ratio / Days to Cover3.8Last Record DateApril 30, 2024Outstanding Shares3,164,837,000 sharesShort Percent of Float0.20%Today's Trading Volume1,425,109 sharesAverage Trading Volume1,788,007 sharesToday's Volume Vs. Average80% Short Selling Takeda Pharmaceutical ? Sign up to receive the latest short interest report for Takeda Pharmaceutical and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTAK Short Interest Over TimeTAK Days to Cover Over TimeTAK Percentage of Float Shorted Over Time Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here Takeda Pharmaceutical Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20246,280,000 shares $82.17 million +5.2%0.2%3.8 $13.09 4/15/20245,970,000 shares $78.71 million -26.5%0.2%3.2 $13.19 3/31/20248,120,000 shares $112.79 million +47.6%0.3%4.4 $13.89 3/15/20245,500,000 shares $79.70 million -12.1%0.2%3.1 $14.49 2/29/20246,260,000 shares $91.36 million -21.7%0.2%3.3 $14.60 2/15/20247,990,000 shares $115.14 million +6.0%0.3%4.2 $14.41 Get the Latest News and Ratings for TAK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 1/31/20247,540,000 shares $110.01 million -11.7%0.2%4.1 $14.59 1/15/20248,540,000 shares $128.44 million +8.4%0.3%4.6 $15.04 12/31/20237,880,000 shares $112.45 million -4.3%0.3%4.3 $14.27 12/15/20238,230,000 shares $112.75 million -8.4%0.3%4.3 $13.70 11/30/20238,980,000 shares $127.02 million +9.1%0.3%4.9 $14.15 11/15/20238,230,000 shares $112.59 million -5.5%0.3%4.5 $13.68 10/31/20238,710,000 shares $118.41 million -7.9%0.3%4.6 $13.60 10/15/20239,460,000 shares $143.22 million +13.0%0.3%4.7 $15.14 9/30/20238,370,000 shares $129.48 million -15.7%0.3%3.7 $15.47 9/15/20239,930,000 shares $162.16 million +53.5%0.3%4.8 $16.33 8/31/20236,470,000 shares $99.61 million -6.0%0.2%3.1 $15.40 8/15/20236,880,000 shares $104.68 million -5.1%0.2%3.2 $15.22 7/31/20237,250,000 shares $110.60 million -11.0%0.2%3.2 $15.26 7/15/20238,150,000 shares $125.35 million -9.3%0.3%4.1 $15.38 6/30/20238,990,000 shares $141.19 million +5.8%0.3%4.7 $15.71 6/15/20238,500,000 shares $137.28 million +7.2%0.3%4.1 $16.15 5/31/20237,930,000 shares $125.57 million +38.2%0.3%3.5 $15.84 5/15/20235,740,000 shares $94.82 million -1.0%0.2%2.4 $16.52 4/30/20235,800,000 shares $96.22 million +3.2%0.2%2.5 $16.59 4/15/20235,620,000 shares $94.47 million -21.4%0.2%2.3 $16.81 3/31/20237,150,000 shares $117.83 million +7.7%0.2%2.6 $16.48 3/15/20236,640,000 shares $106.77 million +32.0%0.2%2.4 $16.08 2/28/20235,030,000 shares $77.21 million -4.7%0.2%1.8 $15.35 2/15/20235,280,000 shares $82.68 million -14.3%0.2%1.9 $15.66 1/31/20236,160,000 shares $97.33 million -29.4%0.2%2.2 $15.80 1/15/20238,730,000 shares $140.55 million +19.3%0.3%3 $16.10 12/30/20227,320,000 shares $114.19 million +1.5%0.2%2.3 $15.60 12/15/20227,210,000 shares $109.16 million +24.3%0.2%2.3 $15.14 11/30/20225,800,000 shares $85.43 million +4.5%0.2%1.9 $14.73 11/15/20225,550,000 shares $76.31 million +39.1%0.2%1.8 $13.75 10/31/20223,990,000 shares $52.75 million -36.9%0.1%1.4 $13.22 10/15/20226,320,000 shares $81.34 million +32.5%0.2%2.2 $12.87 9/30/20224,770,000 shares $61.87 million +38.7%0.2%1.8 $12.97 9/15/20223,440,000 shares $46.13 million +14.3%0.1%1.4 $13.41Do This Today BEFORE Biden Wins in November (Ad)Discover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. TAK Short Interest - Frequently Asked Questions What is Takeda Pharmaceutical's current short interest? Short interest is the volume of Takeda Pharmaceutical shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 6,280,000 shares of TAK short. 0.20% of Takeda Pharmaceutical's shares are currently sold short. Learn More on Takeda Pharmaceutical's current short interest. What is a good short interest ratio for Takeda Pharmaceutical? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TAK shares currently have a short interest ratio of 4.0. Learn More on Takeda Pharmaceutical's short interest ratio. Which institutional investors are shorting Takeda Pharmaceutical? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Takeda Pharmaceutical: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Takeda Pharmaceutical? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.20% of Takeda Pharmaceutical's floating shares are currently sold short. Is Takeda Pharmaceutical's short interest increasing or decreasing? Takeda Pharmaceutical saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 6,280,000 shares, an increase of 5.2% from the previous total of 5,970,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Takeda Pharmaceutical's short interest compare to its competitors? 0.20% of Takeda Pharmaceutical's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Takeda Pharmaceutical: Alnylam Pharmaceuticals, Inc. (2.08%), Genmab A/S (0.42%), BioMarin Pharmaceutical Inc. (2.06%), Teva Pharmaceutical Industries Limited (1.09%), BeiGene, Ltd. (1.93%), Viatris Inc. (3.84%), Sarepta Therapeutics, Inc. (6.02%), Dr. Reddy's Laboratories Limited (0.52%), United Therapeutics Co. (9.42%), Zoetis Inc. (1.13%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Takeda Pharmaceutical stock? Short selling TAK is an investing strategy that aims to generate trading profit from Takeda Pharmaceutical as its price is falling. TAK shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Takeda Pharmaceutical? A short squeeze for Takeda Pharmaceutical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TAK, which in turn drives the price of the stock up even further. How often is Takeda Pharmaceutical's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TAK, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Alnylam Pharmaceuticals Short Squeeze Genmab A/S Short Squeeze BioMarin Pharmaceutical Short Squeeze Teva Pharmaceutical Industries Short Squeeze BeiGene Short Squeeze Viatris Short Squeeze Sarepta Therapeutics Short Squeeze Dr. Reddy's Laboratories Short Squeeze United Therapeutics Short Squeeze Zoetis Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:TAK) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport Society